OXS-3550 is a trispecific ADCC NK Cell engager (TriKE), licensed from the University of Minnesota, that targets the CD16 receptor on NK cells and the CD33 receptor on cancer cells. OXS-3550 targets CD33+ myeloid malignancies, namely acute Myelogenous Leukemia (AML) and Myelodysplastic syndrome.
OXS-3550 is uniquely characterized by the incorporation of IL-15 as an NK cell activator into its design, yielding a trispecific scFv ADCC construct. OXS-3550 binds to the CD16 receptors on NK cells and IL-15 activates the NK cell regardless of the presence of killer cell immunoglobulin-like receptor (KIR) ligands which inhibit NK cell activity. Results obtained in non-clinical models show that this targeted immunotherapy directs immune cells to kill cancer cells while diminishing drug-related toxicity.
A Phase I clinical trial is expected to start in Q2 2018.
A partnership agreement with Altor BioScience Corporation for the use of IL15 was executed in mid 2017.